Calibr and Bill & Melinda Gates Medical Research Institute announce licensing agreement for novel candidate TB treatment compound

LA JOLLA, Calif. and CAMBRIDGE, Mass., Feb. 15, 2023 /PRNewswire/ -- Calibr, a division of Scripps Research dedicated to the "bench to bedside" development of transformative medicines, and the Bill & Melinda Gates Medical Research Institute (Gates MRI), today announced a strategic licensing agreement to advance development of a novel investigational compound for tuberculosis treatment. Under the agreement, Calibr is granting Gates MRI an exclusive license to continue the development of the investigational compound CLB073 for tuberculosis treatment. Calibr will transition CLB073 to Gates MRI for further development.